Evidence map›Paper›PMID 41602384›Full record

ArticleFrontiers in oncology2025

Male occult breast cancer with features highly resembling primary lung cancer: a case report and literature review.

Hao Su, Xinyu Zhao, Huayu Liu, Huantong Shu, Wenjing Li, Zhimin Yang, Mianli Li

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hao Su *Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Xinyu Zhao *Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Huayu LiuDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Huantong ShuDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Wenjing LiDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Zhimin YangDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Mianli LiDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Male breast cancer is an extremely rare form of malignant tumor, and occult breast cancer is also an exceptionally uncommon disease. Given its rarity, diagnosing occult breast cancer in male patients presents significant challenges, and the diagnosis becomes even more difficult when the tumor exhibits characteristics of other neoplasms. For instance, this case report describes a male patient with occult breast cancer presenting with features typical of primary lung cancer. The uniqueness and complexity of this case lie in its clinical presentation: beyond typical axillary lymph node enlargement, the primary imaging feature was an isolated pulmonary mass lesion. This presented significant diagnostic hurdles. For the diagnosis of this case, we administered chemotherapy and intracranial radiotherapy to the patient. Therefore, sharing this rare case aims to heighten clinicians' awareness of differential diagnoses for metastatic cancer with an unknown primary site, particularly when pathological findings of pulmonary lesions do not align with conventional lung cancer markers.

Indexed as

case reportmale breast canceroccult breast cancerprimary lung cancersystemic therapy

Identifiers

PMID41602384
PMCPMC12832376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.